Enanta Pharmaceuticals (ENTA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Company Overview and Financial Position

• Focuses on small molecule drug discovery in virology and immunology, with strong early development capabilities.

• Maintains a robust balance sheet with $248.2 million in cash as of September 30, 2024, a $30 million IRS refund due, and ongoing royalty streams from marketed HCV therapy.

• Legacy in liver viruses and a rich pipeline in respiratory virology, including RSV, COVID-19, and hepatitis B programs.

• Forward-looking plans include clinical development, partnerships, and new program announcements in 2025.

Respiratory Virology Pipeline and Clinical Development

• Zelicapavir (EDP-938), a replication inhibitor for RSV, is the only N-protein inhibitor in clinical development, showing strong efficacy, high resistance barrier, and favorable safety in over 500 patients.

• Pediatric studies demonstrated safety, tolerability, and significant antiviral effect, especially when dosed within three days of symptom onset.

• High-risk adult RSV study is ongoing, targeting 180 patients, with recruitment expected to finish this season and data in Q3.

• EDP-323, an RSV L-protein inhibitor, showed rapid and strong viral load reduction in challenge studies, with potential for best-in-class profile.

• Both RSV candidates have received FDA Fast Track designation and are positioned for potential combination therapy in immunocompromised patients.

Immunology Pipeline and Strategy

• KIT inhibitor program (EPS-1421) targets mast cell-driven diseases like chronic spontaneous urticaria, showing high potency, selectivity, and favorable preclinical properties.

• STAT6 inhibitor aims to offer an oral alternative to biologics for atopic dermatitis and other Th2-driven diseases, with candidate selection planned for H2 2024 and discovery-stage compounds showing high selectivity and in vivo engagement.

• Market potential for type 2 immune disease therapies projected at $35B by 2030, with significant unmet need for oral agents.

• Plans to add a third immunology program in 2024–2025, expanding opportunities in large inflammatory disease markets.